- January 13, 2012
TRIM-edicine was awarded US Patent #7,981,866, on MG53 compositions and methods of use
- May 12, 2011
- May 11, 2011
Dr. Jianjie Ma, Founder of TRIM-edicine, was featured in The Star Ledger.
- February 25, 2011
Dr. Noah Weisleder, Chief Scientific Officer of TRIM-edicine, was awarded the 2011 Kauffman Foundation Postdoctoral Entrepreneur Award. This award recognizes entrepreneurial excellence from those with a Ph.D. that completed postdoctoral studies in the USA.
- November 5, 2010
TRIM-edicine filed a new provisional patent application on developing new diagnostic biomarkers for tissue injury.
- November 1, 2010
TRIM-edicine was awarded a Qualifying Therapeutic Project (QTDP) Grant for the “Treatment of muscular dystrophy by protein therapeutics”. This award will assist in the development of a novel therapy for muscular dystrophy, an unmet medical need.
- September 2, 2010
TRIM-edicine was awarded a Small Business Innovation & Research (SBIR) Grant for “Protein Therapeutics for Muscular Dystrophy”. Several reports indicate the significance of this award leading to the development of new approaches for genetic muscle disorders.
- July 14, 2010
Dr. Jianjie Ma, Founder, and Dr. Noah Weisleder, Chief Scientific officer, are featured in the UMDNJ magazine
- November 17, 2009
TRIM-edicine partners with The Jain Foundation to develop protein therapeutics for muscular dystrophy
- June 4, 2009
Dr. Jianjie Ma’s research on MG53 receives recognition in the Muscular Dystrophy Association’s Quest magazine:
- January 2, 2008
TRIM-edicine, Inc. receives an Edison Innovation Award from the New Jersey Commission on Science & Technology to bring the next generation protein therapies to target cancer and other diseases to the oral healthcare industry.
- January 2, 2008
Dr. Christopher Ferrante receives a New Jersey Technology Fellowship for his work at TRIM-edicine on protein therapeutics in tissue culture wounding models